ACM Global Central Laboratory, a central lab that specializes in delivering high quality testing services designed to optimize clinical trial outcomes, has renewed its College of American Pathologists (CAP) accreditation based on the results of a recent onsite inspection.
ACM Global Central Laboratory
, a central lab that specializes in delivering high quality testing services designed to optimize clinical trial outcomes, has renewed its College of American Pathologists (CAP) accreditation based on the results of a recent onsite inspection.
The College of American Pathology conducted its biennial assessment of ACM U.S. laboratory and pathology operations and found no deficiencies at the company’s laboratory facilities in Rochester, New York. Inspection processes consists of examining quality control procedures and lab records including staff qualifications, equipment, health and safety along with the overall management of the facility. This rigorous process is designed to ensure the highest standard of care for all laboratory patients of central labs worldwide, and is considered equal or more stringent than the U.S. federal government’s own inspection program.
“The CAP survey process is a rigorous, peer-to-peer assessment of our quality and technical proficiency across a comprehensive range of standards. Maintaining this accreditation clearly demonstrates our dedication to high level performance and best practices as a central lab,” said John D’Souza, MD, laboratory director.
To view a complete list of credentials, please visit the site at
www.acmgloballab.com/credentials.aspx
or visit us at
DIA 2013, booth #945
, June 24-28 for more information.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.